ValiRx (LSE:VAL) Total Stockholders Equity : £4.32 Mil (As of Dec. 2024)

View and export this data going back to 2000. Start your Free Trial

What is ValiRx Total Stockholders Equity?

ValiRx's Total Stockholders Equity for the quarter that ended in Dec. 2024 was £4.32 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. ValiRx's Book Value per Share for the quarter that ended in Dec. 2024 was £0.01. The ratio of a company's debt over equity can be used to measure how leveraged this company is. ValiRx's Debt-to-Equity for the quarter that ended in Dec. 2024 was 0.00.

ValiRx Total Stockholders Equity Historical Data

The historical data trend for ValiRx's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ValiRx Total Stockholders Equity Chart

ValiRx Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Stockholders Equity

Get a 7-Day Free Trial

4.91

3.60

4.05

3.22

4.32

ValiRx Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Total Stockholders Equity	Get a 7-Day Free Trial															4.05	4.20	3.22	3.85	4.32

ValiRx (LSE:VAL) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

ValiRx's Book Value per Share for the quarter that ended in Dec. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(4.317	-	0)	/	374.349
	=	0.01

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

ValiRx's Debt-to-Equity for the quarter that ended in Dec. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.01	+	0.001)	/	4.317
	=	0.00

ValiRx Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of ValiRx's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

ValiRx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ValiRx PLC (LSE:VAL) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

EAJF:Germany

Address

D6 Thane Road, MediCity Nottingham, Nottingham, GBR, NG90 6BH

Website

https://www.valirx.com

ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, VAL401 for lung cancer, VAL301, BC201, CLX001, and other drug candidates in their different stages of development.